Univariable analysis of factors associated with a Trichomonas vaginalis transcription-mediated amplification (TV TMA) test result
| Female TV NAAT result | Fisher's exact test p value | Male TV NAAT result | Fisher's exact test p value | |||
|---|---|---|---|---|---|---|
| Positive (N=72) | Negative (N=62) | Positive (N=21) | Negative (N=38) | |||
| Age | 0.327 | 0.439 | ||||
| Not known | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| <20 | 9 (40.9%) | 13 (59.1%) | 2 (33.3%) | 4 (66.7%) | ||
| 20–24 | 19 (48.7%) | 20 (51.3%) | 5 (23.8%) | 16 (76.2%) | ||
| 25–29 | 17 (65.4%) | 9 (34.6%) | 4 (36.4%) | 7 (63.6%) | ||
| 30+ | 27 (57.4%) | 20 (42.6%) | 10 (47.6%) | 11 (52.4%) | ||
| Ethnicity | 0.001* | <0.001* | ||||
| Not known | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | ||
| White | 12 (30.0%) | 28 (70.0%) | 1 (5.6%) | 17 (94.4%) | ||
| Black Caribbean | 40 (69.0%) | 18 (31.0%) | 16 (69.6%) | 7 (30.4%) | ||
| Black African | 3 (50.0%) | 3 (50.0%) | 0 (0.0%) | 2 (100.0%) | ||
| Asian | 2 (33.3%) | 4 (66.7%) | 2 (33.3%) | 4 (66.7%) | ||
| Mixed/other† | 15 (62.5%) | 9 (37.5%) | 2 (22.2%) | 7 (77.8%) | ||
| Country of birth | 0.027* | 0.001* | ||||
| Not known | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| UK | 54 (52.9%) | 48 (47.1%) | 15 (34.9%) | 28 (65.1%) | ||
| Europe‡ | 1 (16.7%) | 5 (83.8%) | 0 (0.0%) | 4 (100.0%) | ||
| Africa | 1 (20.0%) | 4 (80.0%) | 0 (0.0%) | 3 (100.0%) | ||
| Caribbean | 14 (73.7%) | 5 (26.3%) | 6 (100.0%) | 0 (0.0%) | ||
| Asia Pacific | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 3 (100.0%) | ||
| Sexual orientation | 0.438 | 0.500 | ||||
| Not known | 4 (30.8%) | 9 (69.2%) | 0 (0.0%) | 10 (100.0%) | ||
| Heterosexual | 68 (56.7%) | 52 (43.3%) | 21 (44.7%) | 26 (55.3%) | ||
| Same sex partner | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) | ||
| Bisexual | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Self-assessed symptoms | 0.266 | 0.005* | ||||
| Not known | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Yes | 53 (57.5%) | 40 (43.0%) | 10 (66.7%) | 5 (33.3%) | ||
| No | 19 (46.3%) | 22 (53.7%) | 11 (25.0%) | 33 (75.0%) | ||
| Clinically identified signs | 0.158 | 0.057 | ||||
| Not known | 17 (42.5%) | 23 (57.5%) | 9 (28.1%) | 23 (71.9%) | ||
| Yes | 44 (62.9%) | 26 (37.1%) | 7 (70.0%) | 3 (30.0%) | ||
| No | 11 (45.8%) | 13 (54.2%) | 5 (29.4%) | 12 (70.6%) | ||
| Other sexual infection§ | 0.224 | 0.754 | ||||
| Not known | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Yes | 28 (47.5%) | 31 (52.5%) | 4 (30.8%) | 9 (69.2%) | ||
| No | 44 (58.7%) | 31 (41.3%) | 17 (37.0%) | 29 (63.0%) | ||
| Number of partners in the last 3 months | 0.355 | 1.000 | ||||
| Not known | 4 (36.4%) | 7 (63.6%) | 0 (0.0%) | 6 (100.0%) | ||
| 0 or 1 | 53 (53.0%) | 47 (47.0%) | 13 (39.4%) | 20 (60.6%) | ||
| More than 1 | 15 (65.2%) | 8 (34.8%) | 8 (40.0%) | 12 (60.0%) | ||
*Significant at p<0.05.
†Mixed white/black Caribbean or white/black African or mixed white/Asian or Middle Eastern.
‡Rest of Europe excluding UK.
§Chlamydia, gonorrhoea, HIV, syphilis, PID, warts, BV, NSU, Candida, HSV.
NAAT, nucleic acid amplification test; NSU, non-specific urethritis.